Shanghai Hasten Biopharma has entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Insilico Medicine has out-licensed global rights to a small molecule ...
-
-
Recent Updates
- Global rare earth magnet industry impacted by shifts in North American supply management
- Shein’s Bumpy Road to Hong Kong’s IPO Success
- Shein Secures Approval for Hong Kong IPO After Failed Attempts in New York and London
- Shein Secures Approval for Hong Kong IPO After Failed Attempts in New York and London
- Shanghai ranks second among shipping centers
- Exciting Reveals for STACK Wigan’s Upcoming Food and Drink Market Unveiled
- Tencent Enters Talks to Acquire Manus After Meta’s Deal Falls Through
- Tencent Enters Talks to Acquire Manus After Meta’s Deal Falls Through
- Tencent Enters Talks to Acquire Manus After Meta’s Deal Falls Through
- Shein’s Path to Hong Kong IPO Approval Amid Global Strife
Blogroll